Cargando…
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
The chimeric antigen receptor (CAR) is a genetically engineered receptor that combines a scFv domain, which specifically recognizes the tumor-specific antigen, with T cell activation domains. CAR-T cell therapies have demonstrated tremendous efficacy against hematologic malignancies in many clinical...
Autores principales: | Zhang, Qi, Zhang, Zimu, Peng, Meiyu, Fu, Shuyu, Xue, Zhenyi, Zhang, Rongxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214859/ https://www.ncbi.nlm.nih.gov/pubmed/28123893 http://dx.doi.org/10.1080/2162402X.2016.1251539 |
Ejemplares similares
-
CAR-T Cell Therapy: From the Bench to the Bedside
por: Golubovskaya, Vita
Publicado: (2017) -
CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022) -
Angiogenesis in gastrointestinal stromal tumors: From bench to bedside
por: Papadakos, Stavros P, et al.
Publicado: (2022) -
CAR-T cell therapy in ovarian cancer: from the bench to the bedside
por: Zhu, Xinxin, et al.
Publicado: (2017) -
From bench to bedside: the history and progress of CAR T cell therapy
por: Mitra, Aroshi, et al.
Publicado: (2023)